U.S., March 24 -- ClinicalTrials.gov registry received information related to the study (NCT07487909) titled 'A Study of SJP-001 in Comparison With Fexofenadine and Naproxen Administered With Alcohol' on Sept. 29, 2025.
Brief Summary: This will be a double-blind, placebo-controlled study with a 4-way crossover design with subjects administered study drug (SJP-001), placebo, fexofenadine alone and naproxen alone on different study days, in conjunction with a quantity of alcohol estimated to be sufficient to produce a hangover the next day. The amount of alcohol may vary from subject to subject, however each subject will consume the same types and amounts of alcohol on each subsequent treatment day as consumed on the first.
Study Start Date...